Cost-effectiveness of apixaban against current standard of care (SoC) for stroke prevention in atrial fibrillation patients

被引：0
|
作者：
Dorian, P. [1 ]
Kongnakorn, T. [2 ]
Phatak, H. [3 ]
Rublee, D. [4 ]
Kuznik, A. [4 ]
Lanitis, T. [5 ]
Liu, L. [4 ]
Iloeje, U. [7 ]
Lip, G. Y. H. [6 ]
机构：
[1] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[2] United Biosource Corp, Bangkok, Thailand
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Pfizer Inc, New York, NY USA
[5] United Biosource Corp, London, England
[6] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England
[7] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：969 / 969
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF APIXABAN AGAINST CURRENT STANDARD OF CARE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN CHILE
    Vallejos, C.
    Lanas Zanetti, F.
    Castro, C.
    Bustos, L.
    VALUE IN HEALTH, 2014, 17 (03) : A117 - A117
  • [2] Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
    Dorian, Paul
    Kongnakorn, Thitima
    Phatak, Hemant
    Rublee, Dale A.
    Kuznik, Andreas
    Lanitis, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL, 2014, 35 (28) : 1897 - 1906
  • [3] COST-EFFECTIVENESS OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GRECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A524 - A525
  • [4] Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
    Kamae, Isao
    Hashimoto, Yoichiro
    Koretsune, Yukihiro
    Tanahashi, Norio
    Murata, Tatsunori
    Phatak, Hemant
    Liu, Larry Z.
    Tang, Ann C.
    Wang, Peter Feng
    Okumura, Ken
    CLINICAL THERAPEUTICS, 2015, 37 (12) : 2837 - 2851
  • [5] Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Mullin, Rachel
    Blazawski, Jon
    Coleman, Craig I.
    PLOS ONE, 2012, 7 (10):
  • [6] COST-EFFECTIVENESS OF APIXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION: AN KAZAKHSTAN PERSPECTIVE
    Kostyuk, A.
    Almadiyeva, A.
    Nurgozhin, T.
    VALUE IN HEALTH, 2017, 20 (09) : A615 - A615
  • [7] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [8] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Oyaguez, Itziar
    Suarez, Carmen
    Luis Lopez-Sendon, Jose
    Ramon Gonzalez-Juanatey, Jose
    de Andres-Nogales, Fernando
    Suarez, Jorge
    Polanco, Carlos
    Soto, Javier
    PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 485 - 497
  • [9] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Itziar Oyagüez
    Carmen Suárez
    José Luis López-Sendón
    José Ramón González-Juanatey
    Fernando de Andrés-Nogales
    Jorge Suárez
    Carlos Polanco
    Javier Soto
    PharmacoEconomics - Open, 2020, 4 : 485 - 497
  • [10] Cost-effectiveness of apixaban against other novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation patients
    Lip, G. H. Y.
    Kongnakorn, T.
    Phatak, H.
    Kuznik, A.
    Rublee, D.
    Lanitis, T.
    Liu, L.
    Iloeje, U.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 54 - 54
12345